Alexander Birkmann, PhD (he/him/his)

Vice President Virology
AiCuris Anti-Infective Cures AG
Wuppertal, Nordrhein-Westfalen, Germany

Alexander Birkmann, PhD, is a seasoned pharmaceutical professional with over 20 years of experience in antiviral drug development. He has held key positions at Bayer and AiCuris, contributing to the advancement of innovative anti-infective therapies. As Vice President of Virology and HSV Platform at AiCuris, he leads the scientific strategies for the NDA filing and line extension of pritelivir. His expertise spans from early-stage research to late-stage clinical trials, with a focus on herpes simplex virus (HSV) therapeutics.

Disclosure(s): AiCuris Anti-Infectives Cures AG: Employee, Stocks/Bonds (Private Company)

Presentation(s):

• 51 - Pritelivir, a nonnucleoside helicase-primase inhibitor, for the treatment of herpes simplex virus (HSV) infections in Phase 3 clinical development.

  Monday, October 20, 2025
  8:48 AM - 9:00 AM US ET

• 233 - Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for treatment of acyclovir-refractory and/or resistant mucocutaneous HSV infections in immunocompromised subjects

  Monday, October 20, 2025
  3:51 PM - 4:03 PM US ET